Extendicare (TSE:EXE) Hits New 12-Month High – Should You Buy?

Extendicare Inc. (TSE:EXEGet Free Report) shares hit a new 52-week high during trading on Monday . The stock traded as high as C$13.40 and last traded at C$13.33, with a volume of 7781 shares. The stock had previously closed at C$13.35.

Wall Street Analysts Forecast Growth

EXE has been the subject of a number of research reports. BMO Capital Markets upped their price objective on Extendicare from C$11.00 to C$13.50 in a research report on Monday, March 3rd. Cormark upgraded shares of Extendicare to a “moderate buy” rating in a research note on Wednesday, February 19th. Finally, TD Securities boosted their target price on shares of Extendicare from C$10.50 to C$13.00 and gave the company a “hold” rating in a research report on Monday, March 3rd.

Read Our Latest Stock Analysis on Extendicare

Extendicare Stock Up 2.0 %

The company has a quick ratio of 0.98, a current ratio of 0.62 and a debt-to-equity ratio of 283.02. The company has a fifty day simple moving average of C$12.89 and a 200-day simple moving average of C$11.10. The firm has a market cap of C$1.14 billion, a P/E ratio of 17.47 and a beta of 1.26.

Extendicare Increases Dividend

The business also recently disclosed a monthly dividend, which will be paid on Thursday, May 15th. Investors of record on Thursday, May 15th will be paid a dividend of $0.042 per share. The ex-dividend date of this dividend is Wednesday, April 30th. This is an increase from Extendicare’s previous monthly dividend of $0.04. This represents a $0.50 dividend on an annualized basis and a dividend yield of 3.68%. Extendicare’s payout ratio is 61.20%.

Extendicare Company Profile

(Get Free Report)

Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.

Recommended Stories

Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.